Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorCottu, P. H.
dc.contributor.authorRing, A.
dc.contributor.authorMarchetti, P.
dc.contributor.authorCardoso, F.
dc.contributor.authorSalvador, J.
dc.contributor.authorNeven, P.
dc.contributor.authorPapazisis, K.
dc.contributor.authorCampone, M.
dc.contributor.authorBachelot, T.
dc.contributor.authorMenon-Singh, L.
dc.contributor.authorWu, J.
dc.contributor.authorZhou, K.
dc.contributor.authorDe laurentiis, M.
dc.contributor.authoraffiliation[Cottu, P. H.] Inst Curie, Med Oncol, Paris, France
dc.contributor.authoraffiliation[Ring, A.] Royal Marsden Hosp NHS Fdn Trust, Breast Unit, Dept Med, Sutton, Surrey, England
dc.contributor.authoraffiliation[Marchetti, P.] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
dc.contributor.authoraffiliation[Cardoso, F.] Champalimaud Fdn Canc Ctr, Breast Unit, Lisbon, Portugal
dc.contributor.authoraffiliation[Salvador, J.] Hosp Virgen del Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Neven, P.] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Dept Gynaecol Oncol, Campus Gasthuisberg, Leuven, Belgium
dc.contributor.authoraffiliation[Papazisis, K.] Euromed Gen Clin, Dept Oncol, Thessaloniki, Greece
dc.contributor.authoraffiliation[Campone, M.] Inst Canc Res Western France ICO, Med Oncol, St Herblain, France
dc.contributor.authoraffiliation[Bachelot, T.] Leon Berard Ctr, Senol & Gynecol, Lyon, France
dc.contributor.authoraffiliation[Menon-Singh, L.] Novartis Pharmaceut, Global Med Affairs, E Hanover, NJ USA
dc.contributor.authoraffiliation[Zhou, K.] Novartis Pharmaceut, Global Med Affairs, E Hanover, NJ USA
dc.contributor.authoraffiliation[Wu, J.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[De laurentiis, M.] Ist Nazl Tumori IRCCS Fdn Pascale, Breast & Thorac Oncol, Naples, Italy
dc.contributor.funderNovartis Pharmaceuticals Corporation
dc.date.accessioned2025-01-07T15:32:12Z
dc.date.available2025-01-07T15:32:12Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.435
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420404314/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27218
dc.identifier.wosID573469100333
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS379-S380
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRibociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía